Posters

Comparison of hydrophobic vesus hydrophilic intra-ocular lens implantation for combined phacoemulsification of cataract and iStent inject implantation for open angle glaucoma

Poster Details

First Author: M.Georgopoulos UK

Co Author(s):    F. Haddad                    

Abstract Details

Purpose:

It is believed that the structure of hydrophilic intra-ocular lenses (IOLs) allows for more cell proliferation, explaining the higher rates of posterior capsular opacification, phimosis and requirement for Nd:YAG posterior capsulotomy after cataract surgery, as compared to hydrophobic IOLs. In our study, we evaluate the efficacy of iStent Inject (Glaukos, San Clemente, CA 92672 USA) when implanted with hydrophilic or hydrophobic IOLs along a follow up period of 6 months.

Setting:

29 eyes of 29 patients underwent standard phacoemulsification and intra-ocular lens implantation (either hydrophilic or hydrophobic) combined with 2 iStent inject implantation by one surgeon. All cases were uneventful.

Methods:

A longitudinal prospective real-life study including 29 patients who underwent iStent inject with hydrophobic (n=16) (HOYA iSert250 preloaded IOL system, Hoya Medical, Singapore) or hydrophilic (n=13) (RayOne, Rayner intraocular lenses limited, UK) IOL implantation. The IOP and number of classes of IOP-lowering medications were recorded at 1, 3,and 6 months post-operatively. The surgery included 2 iStent implantation and standard phacoemulsification surgery by one surgeon. All operations were uneventful. Age, baseline visual acuity and 24-2 SITA-Fast mean deviation and pattern standard deviation were comparable in both groups. 2-tailed t-test was performed to compare IOP and medication classes in all time points.

Results:

The IOPs were 18.5±3.50, 14.55±2.62, 11.60±3.29 and 13.91±2.84 for the hydrophilic IOL group and 19.68±5.39, 14.38±4.24, 14.00±3.77, and 14.125±2.85 for the hydrophobic IOL group at baseline, 1,3, and 6 months post-operatively, respectively. The medication classes were 2.83±1.94, 1.82±1.40, 0.8±0.84, and 1.25±1.36 for the hydrophilic IOL group and 2.38±1.26, 1.86±1.45, 1.82±1.08, and 1.63±1.54 for the hydrophobic IOL group at baseline, 1,3, and 6 months post-operatively, respectively. Both groups achieved a 25% reduction at 6 months compared to the baseline IOP. None needed further glaucoma procedures in this period.

Conclusions:

Type of IOL does not seem to affect the efficacy of iStent Inject combined with phacoemulsification and Intraocular lens implantation in a real-life study. Longer term studies to evaluate this effect are warranted.

Financial Disclosure:

None